首先，Revolution在JPM大会上透露，2026年将启动KRAS G12D抑制剂RMC-9805的两项三期临床试验，分别针对一线胰腺癌、一线肺癌。

艾伯维 ( 232.19, 8.26, 3.69%) 公司正在就收购专注癌症领域的生物科技公司Revolution Medicines Inc．进行“深入”谈判，这笔交易的价值可能超过200亿美元。

In June, 2018, the political commentator Fareed Zakaria found himself in the Campo de’ Fiori, in the center of Rome, with Steve Bannon, who was then President Trump’s chief strategist. Bannon—whom ...

Revolution Medicines is a clinical-stage pharma company with a market cap of ~6 billion. It has ample liquidity to support its current business plan into 2027. Its pipeline directed entirely towards ...

Revolution Medicines, Inc. shares surged on strong Phase 1 data for daraxonrasib in metastatic pancreatic cancer, showing high response and disease control rates. Daraxonrasib demonstrated superior ...